A new trading day began on Friday, with BioXcel Therapeutics Inc (NASDAQ: BTAI) stock price down -4.26% from the previous day of trading, before settling in for the closing price of $2.82. BTAI’s price has ranged from $1.17 to $13.28 over the past 52 weeks.
Healthcare Sector giant saw their annual sales surged by 6.20% over the last five years. Meanwhile, its annual earnings per share averaged 79.24%.
BioXcel Therapeutics Inc (BTAI) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of BioXcel Therapeutics Inc is 3.88%, while institutional ownership is 4.28%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -5.12 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 79.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 60.31% during the next five years compared to 6.20% growth over the previous five years of trading.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Here are BioXcel Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 60.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.67, a number that is poised to hit -1.02 in the next quarter and is forecasted to reach -3.05 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
Analysing the last 5-days average volume posted by the [BioXcel Therapeutics Inc, BTAI], we can find that recorded value of 1.42 million was lower than the volume posted last year of 4.97 million. As of the previous 9 days, the stock’s Stochastic %D was 30.75%.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 22.14%, which indicates a significant increase from 15.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.28 in the past 14 days, which was lower than the 0.39 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.46, while its 200-day Moving Average is $3.11. Now, the first resistance to watch is $2.89. This is followed by the second major resistance level at $3.07. The third major resistance level sits at $3.19. If the price goes on to break the first support level at $2.59, it is likely to go to the next support level at $2.47. Now, if the price goes above the second support level, the third support stands at $2.29.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
With a market capitalization of 53.05 million, the company has a total of 16,009K Shares Outstanding. Currently, annual sales are 2,270 K while annual income is -59,600 K. The company’s previous quarter sales were 120 K while its latest quarter income was -19,190 K.
